Kymera Therapeutics’ Price Target Soars to $49.00 Following Morgan Stanley’s Upgrade
🌥️Trending News Kymera Therapeutics ($NASDAQ:KYMR) is a leading biopharmaceutical company that is dedicated to developing breakthrough therapies for patients with [...]
Kymara Therapeutics Receives High Rating in Biotech Industry, Positioned for Growth
☀️Trending News Kymara Therapeutics, also known as KYMR, is a clinical-stage biopharmaceutical company that focuses on developing novel, small molecule [...]
Kymera Therapeutics Launches $250M Stock Offering
🌥️Trending News Kymera Therapeutics ($NASDAQ:KYMR) has announced a public offering of 250 million shares of its stock, with an aim [...]
Kymera Therapeutics Stock Fair Value – Analysts Give Kymera Therapeutics, an Average Rating of ‘Moderate Buy’
🌥️Trending News Kymera Therapeutics ($NASDAQ:KYMR), Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, innovative [...]
Kymera Therapeutics Intrinsic Value – KYMERA THERAPEUTICS Reports 43.4% Year-Over-Year Increase in Total Revenue for Q2 of Fiscal Year 2023
☀️Earnings Overview KYMERA THERAPEUTICS ($NASDAQ:KYMR) announced their financial performance for the second quarter of Fiscal Year 2023 on August 3 [...]
Allspring Global Investments Holdings LLC Sells 1075 Shares of Kymera Therapeutics,
☀️Trending News Defense World recently reported that Allspring Global Investments Holdings LLC has sold 1075 shares of Kymera Therapeutics ($NASDAQ:KYMR), [...]
Truist Financial Assigns “Buy” Rating to Kymera Therapeutics Shares
☀️Trending News On Friday, Truist Financial released a research report in which it initiated coverage on Kymera Therapeutics ($NASDAQ:KYMR)' shares [...]
UBS Group AG Significantly Increases Investment in Kymera Therapeutics Despite Q1 Earnings Miss
☀️Trending News UBS Group AG recently made a major move in the life sciences industry with their increased investment in [...]
Kymera Therapeutics Sees Progress with Three Drug Programs
☀️Trending News Kymera Therapeutics ($NASDAQ:KYMR) is a biopharmaceutical company focused on developing innovative treatments for patients with difficult-to-treat diseases. The [...]
Kymera Therapeutics Presents Promising Clinical Data from Phase 1 Trial on KT-474
Trending News ☀️ Kymera Therapeutics ($NASDAQ:KYMR), a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class small molecule therapies, announced [...]
